Where Could The Next Priority Review Voucher Come From?
Executive Summary
There are 21 indications on the list of neglected tropical diseases that qualify for an FDA priority review voucher – an incentive to spur research in those areas – but there aren’t that many drugs in development.
You may also be interested in...
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.